INTRODUCTION AND OBJECTIVES: It has been suggested that anxiety and concerns about cancer may influence both decisions to undergo PSA 'screening' tests and choice of radical treatment over active surveillance (AS) for low risk prostate cancer (PCa). Our objective was to determine whether there is any association between prior history of PSA testing or experience of negative biopsy and uptake of AS among men diagnosed with low risk PCa.
METHODS: This study included all men aged 75 years residing in Stockholm who were diagnosed with low risk PCa from 2008-2014. Data on dates and results of all PSA tests and any prostate biopsy procedures undertaken before diagnosis were obtained from the Stockholm PSA and Biopsy Register, a population-based register of all PSA and biopsy procedures since 2003 among men residing in Stockholm. Associations between PSA/biopsy measures (frequency of PSA testing, mean interval between tests, highest PSA value, PSA velocity and number of prior negative biopsies) and uptake of AS were assessed using multivariable logistic regression, with adjustment for age, education, martial status and comorbidity.
RESULTS: Of the 4336 eligible men with low risk PCa, 47% underwent AS. Uptake of AS was more likely among men older men, those with very low risk disease, those with a family history of PCa and being diagnosed more recently. No association was found with frequency of PSA testing, interval between tests, highest total pre-diagnostic PSA concentration, PSA velocity or previous negative biopsy.
CONCLUSIONS: We found no evidence to suggest that PSA 'screening' behavior or experience of a prior negative biopsy influenced uptake of AS among Swedish men. While availability of individual data on previous PSA tests and biopsy procedures is a major strength of this study, generalizability to settings with different policies and practices relating to PSA testing or PCa treatment may be limited. has become an accepted management strategy for very low risk, low risk, and select cases of favorable intermediate risk localized prostate cancer. Long term data will be critical to continued understanding of which patients are suitable for this strategy and when patients should transition to treatment. We update and investigate long-term follow up in our active surveillance cohort.
METHODS: Under IRB approved protocol, a retrospective cohort study of 1294 men diagnosed with localized prostate cancer was performed at a single tertiary-care center from 1996-2016. In 2008 our group agreed on the following AS guidelines: Gleason 6 (Gleason 7 in select patients with low volume), 3/12 cores positive with 20% in each core, and PSA <10. Our follow-up protocol includes: PSA/DRE every 4-6 months x 3 years, then annually. Mandatory confirmatory 12 core biopsy is performed at 12-18 months with subsequent biopsies at the discretion of the treating physician. In 2014 multiparametric MRI and fusion biopsy became integrated into our practice. Survival analyses were conducted using the Kaplan-Meier method.
RESULTS: The study cohort consisted of 1294 men with a median age at diagnosis of 66.0 (IQR, 60.0-71.0 years). Median follow-up was 6.5 years (Range, 0.1-22.1 years). The median PSA at diagnosis was 5.1 ng/ mL (IQR, 4.0-6.9 ng/mL) with 91% having a PSA < 10 ng/mL. Overall, 97.0% (1256/1294) of patients were Gleason 6 or lower, and 2.9% (38/ 1294) were Gleason 7. 90.8% (1176/1294) were stage T1c. Freedom from intervention was 86% at 5 years, 52% at 10 years, 46.1% at 15 years. 496 patients required treatment during the course of surveillance. Reasons for intervention included: 65.9% (327/496) pathologic progression, 13.9% (69/496) PSA progression, 9.9% (49/496) patient preference, 2.2% (11/496) DRE progression, 2.0% (10/496) metastatic disease. Of patients who were treated, 216 (43.5%) received radiation, 191 (22.4%) received surgery, 54 (10.8%) received brachytherapy, 33 (6.6%) received hormonal therapy, 2 (0.4%) received unknown treatment. On pathologic review after radical prostatectomy, 32/496 (16.8%) patients were pathologic stage T3. Cancer-specific survival was 99.8% at 5 years, 98.6% at 10 years, 94.5% at 15 years. Overall survival was 97.0% at 5 years, 85% at 10 years, 59.4% at 15 years.
